Results 61 to 70 of about 17,264 (156)
Background: Primary non-adherence (PNA)—failure to dispense a newly prescribed medication—is an early barrier to effective treatment. This study aimed to estimate PNA to oral anticoagulants in patients with atrial fibrillation (AF) in Germany and to ...
Karel Kostev +5 more
doaj +1 more source
Pulmonary Embolism—A Century of Progress
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
Anticoagulant treatment: the end of the old agents?
New oral anticoagulants used as single target inhibitors of coagulation enzymes have been developed and tested in extensive trial programmes. Results of most of these trials showed non-inferior and/or superior efficacy and safety compared to ...
Lukas Graf, Dimitrios A Tsakiris
doaj +1 more source
RLIM‐associated neurodevelopmental disorders: From clinical spectrum to molecular mechanisms
RLIM (RNF12) is an E3 ubiquitin ligase essential for mammalian development. Loss‐of‐function variants cause Tønne–Kalscheuer syndrome, while duplications cause Xq13 duplication syndrome, highlighting RLIM dosage sensitivity. This review summarizes the genetics, clinical features, and molecular mechanisms of RLIM‐associated disorders, integrating ...
Madison Landon +4 more
wiley +1 more source
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS +7 more
doaj +1 more source
Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson +2 more
wiley +1 more source
Deep vein thrombosis prophylaxis in patients who undergo knee arthroscopy: a systematic review
Background Knee arthroscopy is one of the most common procedures performed by orthopedic surgeons. A potentially life-threatening complication following this procedure is deep vein thrombosis (DVT). DVT prophylaxis can be obtained both mechanically (e.g.,
Udit Dave +4 more
doaj +1 more source
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton +5 more
wiley +1 more source
ABSTRACT Introduction Bivalirudin is an alternative anticoagulant to heparin and is widely used in pediatric extracorporeal life support (ECLS). Its activity is monitored using activated partial thromboplastin time (aPTT) and/or more specific tests such as plasma‐diluted thrombin time (dTT).
Vadim Kostousov +3 more
wiley +1 more source

